Please use this identifier to cite or link to this item:
|Title:||Intellectual Property Rights and Assessment of the Raw Materials (Crude Drugs) Used in Indian Systems of Medicine|
|Authors:||Ahmad, R U|
|Abstract:||<smarttagtype namespaceuri="urn:schemas-microsoft-com:office:smarttags" name="country-region"><smarttagtype namespaceuri="urn:schemas-microsoft-com:office:smarttags" name="place"> There are two types of Ayurvedic medicines prepared in the country. First is the classical drugs (based on classical literature of the Ayurvedic System of Medicine as given in Schedule-A of the Drug & Cosmetics Act, 1940). Second is the `patent and proprietary’ (P.P.) medicine manufactured by the pharmaceutical industry of the Indian Systems of Medicine (ISM) on their own developed formulations (by adding or deleting in the original classical formulations). In all these formulations, 90% drugs of plant origin are used in their own natural forms as roots, stems, leaves, fruits, and their modified structures and their derivatives like gums, exudates, etc. Since these crude drugs raw material may not have been evaluated scientifically on botanical, pharmacognostical, chemical and pharmacological parameters, etc. it is therefore, necessary to screen them out for various ailments. Pharmaceutical industry of ISM in the country is very large and manufacturing its drugs on the basis of licence issued by the Drug Control Authorities of the respective States. Position of drugs of ISM as to how they are procured, obtained from various resources in the country is not known exactly. The activities attributed to a single plant for various ailments are quite scanty. Their trade history, supply and demand, involvement of national level institutions and their trade market is also not authentically established. Government of India is busy in laying down its standards in the form of pharmacopoeial monographs for quality control purposes. Looking into all these aspects it is necessary that the aspects of intellectual property rights and assessment of raw material (crude drugs) used in ISM is given top priority. The impact of intellectual property-related issues like TRIPS Agreement on the status of crude drugs used in ISM has been discussed. The format proposed by the Forum of Parliamentarians on Intellectual Property Rights is given in the paper and the proposals are given by the author under each item for their adherence to solve the patenting problem of the raw material of ISM industry in the country. </smarttagtype></smarttagtype>|
|ISSN:||0975-1076 (Online); 0971-7544 (Print)|
|Appears in Collections:||JIPR Vol.07(2) [March 2002]|
Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.